Gilead Sciences (GILD) Panoramica del titolo
Gilead Sciences, Inc. è un'azienda biofarmaceutica che scopre, sviluppa e commercializza farmaci nelle aree di necessità medica insoddisfatta negli Stati Uniti, in Europa e a livello internazionale. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 4/6 |
| Crescita futura | 4/6 |
| Prestazioni passate | 6/6 |
| Salute finanziaria | 4/6 |
| Dividendi | 5/6 |
GILD Community Fair Values
Create NarrativeSee what 215 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di Gilead Sciences, Inc.
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | US$134.94 |
| Massimo di 52 settimane | US$157.29 |
| Minimo di 52 settimane | US$97.86 |
| Beta | 0.33 |
| Variazione di 1 mese | -2.91% |
| Variazione a 3 mesi | -13.39% |
| Variazione di 1 anno | 33.04% |
| Variazione a 3 anni | 72.29% |
| Variazione a 5 anni | 95.99% |
| Variazione dall'IPO | 21,223.87% |
Notizie e aggiornamenti recenti
Recent updates
Seeking Alpha • 7h
Gilead's Transition Into A Long-Duration Biotech Platform
Summary Gilead Sciences is executing a successful transition from a mature antiviral company to a diversified therapeutic platform, driving a 34% stock rally. HIV revenue grew 10% YoY, with Yeztugo's explosive PrEP growth and raised guidance to $1B, signaling a durable, long-acting franchise. Oncology is gaining strategic coherence, led by Trodelvy's 37% YoY growth and platform expansion via acquisitions in ADCs, CAR-T, and autoimmune. GILD maintains exceptional profitability and self-funds its pipeline, supporting a Buy rating with 10–15% base-case upside and underappreciated long-term growth. Read the full article on Seeking Alpha
Aggiornamento dell'analisi • May 01
GILD: Future Returns Will Hinge On Executing Oncology And ADC Acquisitions
Analysts have raised the Gilead Sciences fair value estimate by about $2 to $128.42 per share, supported by refreshed models that reflect updated revenue growth, profitability, and future P/E assumptions following a wave of higher Street price targets. Analyst Commentary Street research on Gilead has tilted constructive in recent weeks, with several firms lifting price targets and at least one new Buy rating added.
Aggiornamento dell'analisi • Apr 17
GILD: Oncology Deals And HIV Franchise Will Support Future Earnings
Analysts have raised the price target for Gilead Sciences to $180, citing recent upward revisions across Wall Street that reflect updated views on revenue growth, profitability and oncology deal activity. The core fair value estimate in this framework also remains at $180.Aggiornamento dell'analisi • Apr 03
GILD: HIV And PrEP Franchise Will Support Future Earnings And Margin Strength
Analysts have lifted the fair value estimate for Gilead Sciences to $180 from $159, citing higher modeled revenue growth, a slightly lower discount rate, and support from a wave of recent price target raises and positive initiation commentary on the company’s positioning and operating margins. Analyst Commentary Street research around Gilead Sciences has been active, with several bullish analysts updating their views and price targets in recent weeks.
Aggiornamento dell'analisi • Mar 20
GILD: HIV Franchise And Oncology Expansion Will Shape Bullish Long Term Outlook
The analyst fair value estimate for Gilead Sciences has moved from $132.57 to $157.43, with analysts pointing to stronger modeled revenue growth, slightly higher long term profit margins, and a higher future P/E multiple supported by recent price target hikes and positive views on the company's positioning in large cap biotech. Analyst Commentary Recent Street research on Gilead Sciences reflects a mix of optimism around growth drivers and caution around valuation and competitive risks.Aggiornamento dell'analisi • Mar 05
GILD: Rich HIV Outlook Will Depend On Delivering High-Risk Oncology Acquisitions
Analysts have lifted their Gilead Sciences fair value estimate from $122.64 to $126.09 as they update models to reflect revised revenue growth and profit margin assumptions, along with a slightly higher discount rate and a modestly lower future P/E multiple, following a wave of higher Street price targets in recent weeks. Analyst Commentary Recent Street research around Gilead Sciences shows a mix of optimism and restraint.Aggiornamento dell'analisi • Feb 19
GILD: Elevated Future Expectations Will Hinge On Execution In Oncology
Gilead Sciences' updated analyst price target has moved sharply higher to $122.64 from $91.83, as analysts broadly lift their targets into the $140 to $170 range, citing steadier HIV franchise expectations, contributions from recent launches, and adjusted assumptions for expenses and oncology assets. Analyst Commentary Recent Street research shows a clear tilt toward higher valuation frameworks for Gilead Sciences, with several firms taking their targets into a broad US$140 to US$170 range.Aggiornamento dell'analisi • Feb 05
GILD: Extended HIV And PrEP Strength Will Support Steady Long-Term Earnings Power
Narrative Update: Gilead Sciences Analyst Price Target Shift Analysts have lifted their price targets on Gilead Sciences by as much as US$20, pointing to updated HIV franchise expectations, revised oncology and PrEP assumptions, and refreshed valuation approaches, even as some models incorporate higher IPR&D expenses and adjusted sales forecasts. Analyst Commentary Recent Street research around Gilead centers on two big themes in the models: the durability of the HIV franchise and the ramp in newer areas like PrEP and oncology, with several bullish analysts lifting price targets and reaffirming positive ratings.Aggiornamento dell'analisi • Jan 22
GILD: Extended HIV Franchise Strength Will Support Stronger Long-Term Earnings Power
Analysts have nudged their fair value estimate for Gilead Sciences up to $159 from $153, citing refreshed models that reflect updated HIV franchise expectations, oncology pipeline inputs, and evolving competitive readthroughs from peers in hepatitis and cell therapy. Analyst Commentary Recent Street research around Gilead Sciences has leaned constructive, with several bullish analysts refining their models and resetting price targets while pointing to HIV, oncology, and select liver and autoimmune assets as the key drivers they are watching.Aggiornamento dell'analisi • Jan 07
GILD: HIV PrEP Strength And Oncology Mixed Results Will Shape Outlook
Analysts have nudged their price targets on Gilead Sciences higher, generally toward the US$140 to US$145 range. They cite expectations for stronger HIV PrEP contributions from Yeztugo, a healthier outlook for the broader HIV portfolio including Biktarvy, and ongoing support from oncology and newer launches such as Livdelzi.Aggiornamento dell'analisi • Dec 20
GILD: Extended HIV Exclusivity Will Support Stronger Long-Term Earnings Power
Analysts have raised their fair value estimate for Gilead Sciences to $153 from $140, citing extended Biktarvy exclusivity, a stronger long term HIV growth outlook supported by Yeztugo and PrEP, and increasing conviction in oncology and broader large cap biopharma innovation potential. Analyst Commentary Bullish analysts continue to highlight Gilead as a core large cap biopharma holding, pointing to a healthier long term growth profile in HIV and a strengthening contribution from oncology.Aggiornamento dell'analisi • Dec 06
GILD: Extended HIV Franchise Will Offset Oncology And Policy Uncertainty Ahead
Analysts have nudged their blended price target for Gilead Sciences slightly lower by about $0.20 to the low-$130s, reflecting modestly higher discount rates and more conservative HIV and oncology growth and margin assumptions, even as they highlight extended Biktarvy exclusivity, encouraging Yeztugo uptake, and anito cel driven oncology optionality as key long term value drivers. Analyst Commentary Bullish analysts largely frame the recent price target tweaks as fine tuning within an increasingly constructive long term view, pointing to extended HIV cash flows, a strengthening PrEP opportunity, and optionality in oncology despite early stage competitive readouts.Aggiornamento dell'analisi • Nov 22
GILD: Extended Exclusivity And PrEP Opportunities Will Balance Ongoing Oncology And Policy Pressures
Analysts have modestly raised their price target for Gilead Sciences to $130.83 per share from $129.51. They cite the extended exclusivity period for Biktarvy and improved growth prospects in the HIV market as key drivers for the upward revision.Aggiornamento dell'analisi • Nov 08
GILD: HIV Business Strength And Patent Extension Will Balance Oncology Risks Ahead
Gilead Sciences' price target has been raised by analysts from $127 to $145. This reflects confidence in stable HIV business trends and improved execution, which offsets ongoing oncology and cell therapy challenges.Aggiornamento dell'analisi • Oct 25
Patent Extension And Policy Decisions Will Drive Access To Advanced Therapies
Gilead Sciences' analyst price target has increased from $126 to $127 per share. Analysts point to continued strong uptake of the Yeztugo launch in HIV and the recent Biktarvy patent extension as supporting factors, despite some pipeline setbacks.Aggiornamento dell'analisi • Oct 10
Global Healthcare Trends Will Expand Access To Advanced Therapies
Gilead Sciences saw its analyst price target increase from $124.91 to $126.31. Analysts cited improved sales forecasts for key HIV treatments and enhanced revenue growth expectations as the primary drivers of the upward revision.Aggiornamento dell'analisi • Sep 04
Global Healthcare Trends Will Expand Access To Advanced Therapies
Analysts remain constructive on Gilead Sciences, citing strong HIV franchise performance, positive FDA developments, and favorable regulatory tailwinds offsetting minor pipeline setbacks, resulting in an unchanged consensus price target of $124.37. Analyst Commentary Yeztugo’s FDA approval and clean label, strong clinical data, and convenient twice-yearly dosing are seen as key drivers for Gilead’s HIV franchise growth, with analysts generally positive on long-term adoption despite initial ramp expectations being slow and some cannibalization of Descovy anticipated.Articolo di analisi • Jul 27
Does Gilead Sciences (NASDAQ:GILD) Have A Healthy Balance Sheet?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Articolo di analisi • May 15
Statutory Profit Doesn't Reflect How Good Gilead Sciences' (NASDAQ:GILD) Earnings Are
Even though Gilead Sciences, Inc.'s ( NASDAQ:GILD ) recent earnings release was robust, the market didn't seem to...Seeking Alpha • Apr 25
Gilead Sciences Q1 Earnings Review: HIV Division Masks Underperformance
Summary Gilead Sciences' Q1 2025 earnings report shows a slight decline in product sales, primarily due to lower Veklury sales and oncology inventory issues. The HIV division remains Gilead's strongest performer, with Biktarvi leading the charge, while oncology investments have yet to yield significant returns. Key upcoming milestones include the FDA decision on lenacapavir, a potential blockbuster HIV therapy, and various oncology and cell therapy data readouts. Despite recent share price growth, I am downgrading GILD stock to "Hold" due to concerns over oncology and cell therapy prospects and limited upside potential. Read the full article on Seeking AlphaNuova analisi • Apr 08
New HIV, Livdelzi And CAR T Options Will Expand Reach
Gilead's innovation in HIV and oncology treatments supports revenue growth and market expansion in these therapeutic areas.Seeking Alpha • Mar 16
Gilead: Growth Constraints Lead To Rating Downgrade Following 50% Rally
Summary Gilead's HIV portfolio remains dominant but faces Medicare Part D pricing pressure, limiting future growth potential. New launches like Livdelzi provide growth opportunities but are unlikely to overcome the flat HIV segment forecast. DCF modeling shows Gilead is priced for 0% growth, which aligns with near-term revenue expectations. Heavy reliance on HIV franchise (72% of revenue) creates vulnerability despite diversification efforts in oncology. Following a 57% rally since June, Gilead now trades at fair value relative to its modest growth outlook, meriting a rating downgrade to "hold" and "market perform." Read the full article on Seeking AlphaRendimenti per gli azionisti
| GILD | US Biotechs | US Mercato | |
|---|---|---|---|
| 7D | 1.1% | 1.5% | 1.5% |
| 1Y | 33.0% | 41.7% | 25.5% |
Ritorno vs Industria: GILD ha avuto una performance inferiore rispetto al US Biotechs che ha registrato un rendimento 41.7 % nell'ultimo anno.
Rendimento vs Mercato: GILD ha superato il mercato US che ha restituito 25.5 % nell'ultimo anno.
Volatilità dei prezzi
| GILD volatility | |
|---|---|
| GILD Average Weekly Movement | 3.1% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.0% |
| 10% least volatile stocks in US Market | 3.2% |
Prezzo delle azioni stabile: GILD non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato US.
Volatilità nel tempo: La volatilità settimanale ( 3% ) di GILD è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 1987 | 17,000 | Dan O'Day | www.gilead.com |
Gilead Sciences, Inc. è un'azienda biofarmaceutica che scopre, sviluppa e commercializza farmaci nelle aree di necessità medica insoddisfatta negli Stati Uniti, in Europa e a livello internazionale. L'azienda fornisce Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza e Yeztugo per il trattamento dell'infezione da HIV-1 nei pazienti. Fornisce inoltre Epclusa, Livdelzi e Vemlidy per il trattamento dell'epatite cronica da virus C, della colangite biliare primaria e dell'epatite cronica da virus B; Tecartus, una terapia a base di cellule T per il trattamento di pazienti adulti; Trodelvy, un'iniezione per uso endovenoso; Yescarta, una sospensione per infusione endovenosa, è una terapia a base di cellule T CAR per il trattamento di pazienti adulti.
Gilead Sciences, Inc. Riepilogo dei fondamenti
| GILD statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | US$165.77b |
| Utili (TTM) | US$9.22b |
| Ricavi(TTM) | US$29.74b |
18.2x
Rapporto P/E5.6x
Rapporto P/SGILD è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| GILD Conto economico (TTM) | |
|---|---|
| Ricavi | US$29.74b |
| Costo del fatturato | US$6.14b |
| Profitto lordo | US$23.60b |
| Altre spese | US$14.39b |
| Utili | US$9.22b |
Ultimi utili riportati
Mar 31, 2026
Prossima data di guadagno
n/a
| Utile per azione (EPS) | 7.42 |
| Margine lordo | 79.37% |
| Margine di profitto netto | 30.99% |
| Rapporto debito/patrimonio netto | 94.6% |
Come si è comportato GILD nel lungo periodo?
Vedi performance storica e confrontoDividendi
2.4%
Rendimento attuale del dividendo43%
Rapporto di remunerazioneGILD paga dividendi affidabili?
Vedere la storia dei dividendi e i benchmark di GILD| Gilead Sciences date dei dividendi | |
|---|---|
| Data di stacco del dividendo | Jun 15 2026 |
| Data di pagamento dei dividendi | Jun 29 2026 |
| Giorni fino al dividendo Ex | 32 days |
| Giorni prima della data di pagamento dei dividendi | 46 days |
GILD paga dividendi affidabili?
Vedere la storia dei dividendi e i benchmark di GILDAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/12 21:10 |
| Prezzo dell'azione a fine giornata | 2026/05/12 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Gilead Sciences, Inc. è coperta da 66 analisti. 21 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| David Toung | Argus Research Company |
| Brian Skorney | Baird |
| James Birchenough | Barclays |